Suchergebnisse
10
Alles
Such-Filter
Organisationen
Pharming Group N.V.
Pharming Group to participate in April investor conferences
28. März 2025 03:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, March 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
20. März 2025 02:00 ET
|
Pharming Group N.V.
Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
13. März 2025 02:00 ET
|
Pharming Group N.V.
Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total...
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
04. März 2025 09:15 ET
|
Pharming Group N.V.
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of...
Pharming Group to participate in March investor conference
28. Februar 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
27. Februar 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year...
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
20. Februar 2025 16:00 ET
|
Pharming Group N.V.
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to...
Pharming Group to participate in February investor conference
10. Februar 2025 02:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, February 10, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
07. Februar 2025 16:00 ET
|
Pharming Group N.V.
This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to...
Pharming Group to convene Extraordinary General Meeting of Shareholders
21. Januar 2025 12:00 ET
|
Pharming Group N.V.
Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General Meeting of...